article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary. Key Responsibilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Missouri Republican,Michael Davis, proposes adding access to LSD, MDMA, peyote, and psilocybin as treatment options

Cannabis Law Report

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Missouri has had its own version of right-to-try since 2014.

article thumbnail

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Cannabis Law Report

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. 2014; 7: 115-124. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. billion in 2030.

article thumbnail

MAPS – Position: European Regulatory Lead

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary. Key Responsibilities.

article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52